Publication Name	World Journal of Methodology
Manuscript ID	60504
Country	Italy

Received	2020-11-01 13:01
Peer-Review Started	2020-11-01 13:02
To Make the First Decision
Return for Revision	2020-11-30 01:46
Revised	2020-12-02 10:09
Second Decision	2021-03-23 07:13
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-03-29 03:46
Articles in Press	2021-03-29 03:46
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-04-29 07:39
Publish the Manuscript Online	2021-05-12 13:46

ISSN	2222-0682 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Systematic Reviews
Article Title	Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis
Manuscript Source	Invited Manuscript
All Author List	Fausto Petrelli, Sara Cherri, Michele Ghidini, Gianluca Perego, Antonio Ghidini and Alberto Zaniboni
ORCID	Author(s) ORCID Number Fausto Petrelli http://orcid.org/0000-0001-9639-4486
Funding Agency and Grant Number
Corresponding Author	Fausto Petrelli, MD, Doctor, Medical Sciences, Asst Bergamoo Ovest, Piazzale ospedale 1, Milano 20124, Italy. faustopetrelli@gmail.com
Key Words	Tocilizumab; COVID-19; Pandemic; Treatment; Meta-analysis; Review
Core Tip	Coronavirus disease 2019 (COVID-19) infection is associated with a citokine storm during acute phase. Interleukin-6 is a key player in this systemic inflammation. We evaluated the effect of tocilizumab (TCZ) on the outcomes of COVID-19 pneumonia. Mortality was reduced in patients treated with TCZ (Odds ratio =0.64, 95% confidence intervals: 0-47-0.87; P < 0.01). We conclude that TCZ may improve outcome of COVID-19 infected patients.
Publish Date	2021-05-12 13:46
Citation	Petrelli F, Cherri S, Ghidini M, Perego G, Ghidini A, Zaniboni A. Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis. World J Methodol 2021; 11(3): 95-109
URL	https://www.wjgnet.com/2222-0682/full/v11/i3/95.htm
DOI	https://dx.doi.org/10.5662/wjm.v11.i3.95

Full Article (PDF)	WJM-11-95.pdf
Full Article (Word)	WJM-11-95.docx
Manuscript File	60504_Auto_Edited_LM.docx
Answering Reviewers	60504-Answering reviewers.pdf
Audio Core Tip	60504-Audio core tip.m4a
Biostatistics Review Certificate	60504-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	60504-Conflict-of-interest statement.pdf
Copyright License Agreement	60504-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	60504-Language certificate.pdf
Peer-review Report	60504-Peer-review(s).pdf
Scientific Misconduct Check	60504-Bing-Wang JL-1.jpg
Scientific Misconduct Check	60504-Scientific misconduct check.pdf
Scientific Editor Work List	60504-Scientific editor work list.pdf